Haseeb Khan PhD (Aligarh Muslim University)
Founder, BiomedSoft LLC, Jersey City, NJ · United States
Editorial leadership for Journal of Advanced Pharmaceutical Science And Technology ISSN 2328-0182
Research interests
- Clinical Biochemistry
- Disease Markers
- Drug Interactions
- Nanomedicine
Biography
Dr. Haseeb Khan is the Founder of BiomedSoft LLC in Jersey City, NJ, United States. He obtained his PhD from Aligarh Muslim University, India, and received scientific training in the USA, UK, Denmark, and Finland. He is a Fellow of the Royal College of Pathologists and the Royal Society of Chemistry, UK. His research contributions span analytical and molecular biosciences, environment and wildlife studies, and nanotoxicology, with his most-cited work examining the histopathological effects of gold nanoparticles in mice (2018, 169 citations). He has authored over 30 indexed publications and serves on the editorial boards of several international journals.
Selected publications
- Histopathology of the Liver, Kidney, and Spleen of Mice Exposed to Gold Nanoparticles 2018 cited 169×
- Fabrication of multifunctional cellulose/TiO2/Ag composite nanofibers scaffold with antibacterial and bioactivity properties for future tissue engineering applications 2020 cited 46×
- Potential risk factors for dental caries in Type 2 diabetic patients 2018 cited 36×
- Investigations on Binding Pattern of Kinase Inhibitors with PPARγ: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation Studies 2017 cited 31×
- Reproductive Toxicity of Pomegranate Peel Extract Synthesized Gold Nanoparticles: A Multigeneration Study in C. elegans 2019 cited 26×
- Protective effects of a natural herbal compound quercetin against snake venom-induced hepatic and renal toxicities in rats 2018 cited 23×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JAPST for your work?
This journal is guided by Haseeb Khan (Founder, BiomedSoft LLC, Jersey City, NJ) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.